Isis picks up $10M from Biogen; Galapagos homes in on CF R&D;

@FierceBiotech: Pfizer, Novartis race to market with 'breakthrough' meningitis B vaccines. Story | Follow @FierceBiotech

@JohnCFierce: Selecta ramps up a gout program, gets more cash for vaccine R&D. News | Follow @JohnCFierce

@DamianFierce: As you head home from 2014 ADA, check out FiercePharma's rundown of the best-selling diabetes drugs. More | Follow @DamianFierce

> Isis Pharmaceuticals ($ISIS) bagged a $10 million milestone payment in its ongoing work with Biogen Idec ($BIIB) in developing treatments for neurological disorders. Item

> BioTime's ($BTX) Asterias Biotherapeutics subsidiary raised $13 million in equity financing, money it'll use to advance its regenerative medicine candidates. News

> After selling off its CRO businesses, Galapagos ($GLPG) is focusing in on R&D, highlighting the potential of its work in cystic fibrosis alongside partner AbbVie ($ABBV). More (PDF)

Medical Device News

@FierceMedDev: ICYMI: Done deal: Medtronic to buy Covidien for $42.9B. Story | Follow @FierceMedDev

@StacyALawrence: iWatch to unite Apple healthcare strategy? Article | Follow @StacyALawrence

@MichaelGFierce: UPenn team combats Parkinson's with immunotherapy that targets neuron killers. More | Follow @MichaelGFierce

@EmilyWFierce: "Strokefinder" microwave helmet could provide a portable, quick way to diagnose strokes in ambulances. News | Follow @EmilyWFierce

> Flurry of M&A deals points to industrywide move to consolidate. More

> Tissue Regenix talks up acquisition after recent product launch. Story

> Edwards gets FDA nod to begin U.S. rollout of its Sapien XT TAVR. Article

Pharma News

@FiercePharma: Our newest report, now live: The top 10 best-selling diabetes drugs of 2013. Story | Follow @FiercePharma

@TracyStaton: Trending now at FiercePharma: Novo Nordisk lays out plans to recruit 6,000 workers in R&D, production. More | Follow @TracyStaton

@EricPFierce: India's Lupin wants to buy capacity in EU in biosimilars, inhalation drugs to build markets there. News | Follow @EricPFierce

@CarlyHFierce: Expecting hostile suitors, Shire brings in reinforcements. More | Follow @CarlyHFierce

@JustinHFierce: The USDA licenses first vaccine for Porcine Epidemic Diarhea Virus (PEDv), 7mil pigs already dead since outbreak. News | Follow @JustinHFierce

> Merck seeks sanctions against Brown U doc over Vioxx comments. More

> With Pfizer's bid dead, AstraZeneca chief promises eyes on goal. Article

Biotech Research News

> UPenn team combats Parkinson's with immunotherapy that targets neuron killers. More

> Party drug ketamine shows potential as rapid-acting therapy for depression. Article

> Copper compound increases survival in mice with ALS. News

> Type 1 diabetes reversed in mice. Item

> Think tank: $4.5B investment in BRAIN project too modest. Report

> NIH would get 2% budget hike under Senate bill. More

Pharma Manufacturing News

> Health Canada lets Biolyse restore production of paclitaxel. News

> OSHA fines a Wisconsin API maker that no longer exists almost half a million. More

> FDA approves Novartis U.S. vaccine plant it is trying to sell. Article

> India's Lupin ready to spend $1B to bulk up in EU. Story

> Grand River Aseptic Manufacturing gets $9.8M boost. Report

> FDA says Apotex India plant has faked data for years. Item

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.